SCHOTT Pharma Plans to Invest US$371 million in California, USA
Introduction:
SCHOTT Pharma plans to invest US$371 million to open new prefillable syringe manufacturing facility in California, USA.
Features:
The new site will be the first in U.S. region dedicated to producing prefillable polymer syringes essential for addressing the demand for deep-cold storage and transportation of mRNA medications.
In addition, Moreover, this site will also possess the capability to manufacture glass prefillable syringes tailored for GLP-1 therapies, used, for instance, in treating conditions such as diabetes or obesity.
With this new facility expanding the U.S. supply chain, aims to meet the growing demand for syringes used in administering life-saving injectable medications, vaccines, and various other applications. By 2030, it plans to triple its output of glass and polymer syringes in the region.
Moving production to the United States will decrease lead times and substantially reduce transportation expenses. Additionally, it will safeguard against potential scarcities of essential drugs, reinforcing preparedness for pandemics.
This project will create 401 new jobs in the area. Construction is expected to start by the end of 2024, and the facility should start operating in 2027.
Specifications:
Name SCHOTT Pharma
Type New Construction
Budget US$371 million
Year 2027
